Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Abstract Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor microenvironment contains infiltrating immune cells including cytotoxic T cells; however, there is an overall immunosuppressive mi...
Main Authors: | S. K. Daniel, K. M. Sullivan, K. P. Labadie, V. G. Pillarisetty |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-04-01
|
Series: | Clinical and Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40169-019-0226-9 |
Similar Items
-
Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis
by: Xiushen Li, et al.
Published: (2023-03-01) -
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
by: Raefa Abou Khouzam, et al.
Published: (2023-02-01) -
Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy
by: Concetta Meo, et al.
Published: (2024-01-01) -
Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
by: Tadataka Takagi, et al.
Published: (2023-04-01) -
Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
by: Bin Wang, et al.
Published: (2021-01-01)